Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Pomdoctor management says H1 2026 net loss widens as share-based compensation drives operating expenses higher

Pomdoctor management says H1 2026 net loss widens as share-based compensation drives operating expenses higher

BitgetBitget2026/09/29 20:03
  • Pomdoctor management commentary for the six months ended June 30, 2026 cited net revenue up 6% to RMB 185 million.
  • Mix shifted toward internet hospital revenue, up 49.3% to RMB 100.26 million, led by online pharmacy sales growth.
  • Pharmaceutical supply chain revenue fell 21% to RMB 84.74 million, driven by reduced wholesale with a large customer.
  • Gross margin slipped to 13.7% from 16.2% as online pharmacy added more best-selling products with lower margins.
  • Net loss widened to RMB 238.17 million, reflecting RMB 215.7 million in share-based compensation tied to marketing, administrative, R&D services.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pomdoctor Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-104640), on September 29, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Amid doubts about demand, Bank of America backs Apple (AAPL.US)! iPhone Duo pre-sale will be a crucial test

Despite investors weighing the market response to the latest iPhone product line amid price increases and a phased launch, Bank of America still maintains a "Buy" rating on Apple with a target price of $370.

智通财经•2026/10/13 08:01
Amid doubts about demand, Bank of America backs Apple (AAPL.US)! iPhone Duo pre-sale will be a crucial test